GlaxoSmithKline

Welcome to the 'GlaxoSmithKline' tag page at Technorati. This page features content from the farthest reaches of the Blogosphere that authors have "tagged" with 'GlaxoSmithKline'.

Latest blogosphere posts tagged “GlaxoSmithKline”

• Pharmalot… Pharmalittle… Morning Edition

  
  Pharmalot — Authority: 589
  Top of the morning, everyone. And a pleasant one, it is. Of course, rousting one of the short people from bed is proving challenging today - those of you with adolescents may understand. Still, we soldier on. And that calls for a cup of stimulation or two. While we brace ourselves, here are a few items to help you ...
  11 hours ago

• Swine FLU A H1N1: GSK signs agreement with the WHO to donate 50 million doses of vaccine to developing countries

  
  SALUTE DOMANI ? IL PORTALE DEL BENESSERE — Authority: 149
  GlaxoSmithKline (GSK) today announced that it has signed an agreement with the World Health Organization (WHO) to donate 50 million doses of its adjuvanted pandemic H1N1 influenza vaccine to WHO for distribution to developing countries most in need. GSK is working with WHO and health authorities to prepare for ...
  14 hours ago

• Seattle’s Kineta Rakes in Half of $13M Federal Contract to UW For Vaccine Boosters

  
  Xconomy — Authority: 708
  Biotech , vaccines , startups Luke Timmerman wrote: Kineta, the Seattle-based developer of drugs for autoimmune diseases , has won about half of a $13 million federal contract awarded to the University of Washington to create new compounds which might be used to boost the effectiveness of vaccines ...
  14 hours ago

• 
  NYT > Theater — Authority: 915
  
  1 day ago

• Concert Starts HIV Trial, Bags $12M From Glaxo to Help Challenge Gilead’s Once-Daily Pill

  
  Xconomy — Authority: 708
  Biotech , deals , HIV Luke Timmerman wrote: Concert Pharmaceuticals, the Lexington, MA-based company that chemically modifies existing drugs to make them more attractive, has started human testing of an HIV medication which it hopes will help GlaxoSmithKline wrestle back market share it has been losing ...
  1 day ago

• The Trouble with Transparency

  
  PharmExec Blog — Authority: 485
  Jacky Law Guest blog by Jacky Law A couple of weeks ago I attended an industry awards dinner and had an interesting conversation with an eminent doctor who shall remain nameless. The doctor in question works in a highly specialized area and frequently talks about her research at conferences around the world. ...
  4 days ago

• Pharmalot… Pharmalittle… The Weekend Nears

  
  Pharmalot — Authority: 589
  After a long and busy week, a little downtime is in order. What will you be doing this weekend? The pumpkin patches are likely empty, so perhaps raking leaves is the thing to do - the exercise can’t hurt and leaf blowers, after all, are noisy. Or perhaps a long walk with the dog? Maybe toss a football? Our agenda ...
  4 days ago

• Pneumococcal disease: World Health Organization Grants Prequalification for Global Use to GSK’s Vaccine

  
  SALUTE DOMANI ? IL PORTALE DEL BENESSERE — Authority: 149
  The World Health Organization (WHO) has awarded prequalification for global use to Synflorix™ , GlaxoSmithKline Biologicals’ pneumococcal conjugate vaccine. The prequalification is the first for a vaccine against pneumococcal disease, which is a life-threatening disease affecting many children under five in ...
  4 days ago

• Build it Boldly, and Pharma Will Come—and More Wisdom from Boston’s Biotech and Pharma Elite at Xconomy Forum

  
  Xconomy — Authority: 708
  Life Sciences , innovation , Xconomy Forum Ryan McBride wrote: It was an inspiring afternoon yesterday at Xconomy’s latest event, “Pharma’s Bet on Boston Innovation,” in Cambridge, MA. Local industry pioneers such as Millennium CEO Deborah Dunsire and Sirtris CEO Christoph Westphal talked about ...
  5 days ago

• Promise of a New Lupus Treatment is a Groundbreaking Achievement

  
  Science Blog - Science news straight from the source — Authority: 617
  BENLYSTA™ Successful in Second Pivotal Clinical Trial
  5 days ago

• FEI Europe Track Spotlight: Generate Partnerships

  
  Front End of Innovation — Authority: 123
  Well be alternating between speaker profiles and track spotlights from the event every Wednesday leading up to FEI Europe. This week were focusing on the Generate Partnerships track, which will help make open innovation & external collaboration work. Moving beyond the fundamentals- you will discover specific ...
  6 days ago

• See You There Tomorrow at Pharma’s Bet on Boston Innovation

  
  Xconomy — Authority: 708
  Xconomy Forum , Life Sciences , SeeYouThere Luke Timmerman wrote: I’m dashing this message off right before I get on a plane for Xconomy’s big event tomorrow afternoon: “ Pharma’s Bet on Boston Innovation .” Only a few tickets are left for this gathering at the Hyatt Regency in Cambridge, MA. ...
  1 week ago

• Connecticut Attorney Gen’l Probes Vaccine Makers

  
  Pharmalot — Authority: 589
  The state is investigating complaints of price fixing and preferential treatment in the distribution of seasonal flu vaccine. Attorney General Richard Blumenthal’s office told reporters it has written to 13 manufacturers and distributors of seasonal flu vaccine, requesting details on price, supply levels and ...
  1 week ago

• Second Successful Trial for Lupus Drug

  
  EmpowHer.com - Site Activity Feed — Authority: 546
  An experimental lupus drug called Benlysta (belimumab) was effective in its second large clinical trial, and drug makers Human Genome Sciences and GlaxoSmithKline will seek European and U.S. approval of the drug in the first half of 2010. read more
  1 week ago

• Is Big Pharma Choosing Patients over Patents?

  
  PharmTech Talk — Authority: 120
  The pharmaceutical and biopharmaceutical industries have jealously guarded their intellectual property for years. Companies routinely use patents to prevent competitors from making generic versions of their drugs. When pipelines have weakened, companies have developed new formulations or delivery methods to extend ...
  1 week ago

• Germans Unhappy With Alternative Swine Flu Vaccine For Politicians

  
  Bajan Global Report — Authority: 429
  Damage control is the name of the game in Berlin on Monday as politicians rush to deny that they are receiving a better, safer swine flu vaccine than ordinary Germans. The first of 50 million doses arrived in Germany on Monday.One might think that the arrival in Germany of the first of 50 million doses [...]
  1 week ago

• Who Ya Gonna Call? Filibuster!

  
  HYSTERICAL RAISINS — Authority: 496
  From Joe Conason at Salon : If Democrats are disappointed by Joe Lieberman’s threat to filibuster any healthcare reform bill that includes a public option, they shouldn’t be. Despite all of his past promises to support universal healthcare, nothing was more predictable than the Connecticut senator’s ...
  1 week ago

• Obama Administration Launches Deceptive Swine Flu Propaganda Blitz To Counter Growing Criticism from Scientific and Medical Community By Richard Gale and Dr. Gary Null

  
  Creative-i — Authority: 147
  President Obama and his top health officials are engaging in a major public relations effort to divert attention away from whether its swine flu vaccine is effective and safe – to whether there is enough of it to go around. And the media, as always, is cooperating fully. This echoes the way media debate was ...
  1 week ago

• Reuters article cites changes in health care reform bills as evidence activists are prevailing despite insurance industry lobbyists

  
  Audacity — Authority: 414
  For-profit insurance is unique to the U.S. health care system. No other developed country has a profit motive warping the payment of health care, driving up costs. That’s arguably the key reason Americans spend a much higher share income on health care, and why small business owners shoulder a greater share of the ...
  1 week ago

• GlaxoSmithKline PLC (NYSE:GSK) – 3Q 09 results in line with our expectations.

  
  ResearchOracle.com — Authority: 155
  GlaxoSmithKline PLCs (GSK) results were in line with our estimates in 3Q 09. Therefore, our fundamental outlook remains unchanged and we maintain our BUY rating for the common stock. We will reassess our common stock target price and rating in our next full update report. We continue to anticipate a positive currency ...
  1 week ago

Comments about GlaxoSmithKline